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Abstract: Heart rate variability (HRV) reﬂ  ects both cardiac autonomic function and risk of 
sudden arrhythmic death (AD). Indices of HRV based on linear stochastic models are indepen-
dent risk factors for AD in postmyocardial infarction (MI) cohorts. Indices based on nonlinear 
deterministic models have a higher sensitivity and speciﬁ  city for predicting AD in retrospec-
tive data. A new nonlinear deterministic model, the automated Point Correlation Dimension 
(PD2i), was prospectively evaluated for prediction of AD. Patients were enrolled (N = 918) 
in 6 emergency departments (EDs) upon presentation with chest pain and being determined 
to be at risk of acute MI (AMI)  7%. Brief digital ECGs ( 1000 heartbeats, ∼15 min) were 
recorded and automated PD2i results obtained. Out-of-hospital AD was determined by modiﬁ  ed 
Hinkle-Thaler criteria. All-cause mortality at 1 year was 6.2%, with 3.5% being ADs. Of the AD 
fatalities, 34% were without previous history of MI or diagnosis of AMI. The PD2i prediction 
of AD had sensitivity = 96%, speciﬁ  city = 85%, negative predictive value = 99%, and relative 
risk  24.2 (p   0.001). HRV analysis by the time-dependent nonlinear PD2i algorithm can 
accurately predict risk of AD in an ED cohort and may have both life-saving and resource-saving 
implications for individual risk assessment.
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Introduction
Analysis of heart rate variability (HRV) noninvasively provides real-time trending of 
beat-to-beat changes in the ECG that reﬂ  ect changes in cardiac autonomic function 
and performance (Askelrod et al 1981; Stein et al 1994). Abnormalities are indicated 
by low indices of HRV (Stein et al 1994). Such diminished measures are associated 
with increased susceptibility to ventricular arrhythmias and sudden arrhythmic death 
(AD) (Kleiger et al 1987; Stein et al 1994; Ho et al 1997).
Decreased HRV indices are frequently found among patients with myocardial 
infarction (acute MI [AMI] or post MI), congestive heart failure (CHF), diabetes, and 
alcoholic cardiomyopathy (Stein et al 1994). The indices are independent risk factors 
for mortality in the post MI and advanced CHF patients (Kleiger et al 1987; Coumel 
et al 1991; Stein et al 1994; Ho et al 1997). HRV indices based on brief observational 
windows (10–15 min) have the same predictability for sudden AD as those based on 
24-hour records (Fei et al 1996).
The various HRV indices have not been widely adopted because no single mea-
surement has yet demonstrated sufﬁ  cient statistical predictability of lethal arrhyth-
mogenesis in individuals, ie, they have inadequate sensitivity and speciﬁ  city to be 
of clinical utility. The limited performance is related to assumptions of the model 
underlying the algorithm used to measure the beat-to-beat variation. For example, an 
algorithm such as Standard Deviation of Normal to Normal beats (SDNN), which is Therapeutics and Clinical Risk Management 2008:4(4) 690
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based on a linear stochastic model, presumes the data varia-
tion is random and is distributed around a mean. We know, 
however, that heartbeat intervals have internal correlations, 
are not random, and thus violate the model assumptions. In 
contrast, an algorithm based on a nonlinear deterministic 
model presumes that the variation is caused physiologically 
and has no beat-to-beat errors. Thus, the nonlinear measure 
should be inherently more accurate because the data ﬁ  t the 
underlying model.
The consideration about the fundamental nature of the 
cardiac rhythm and its measurement has stimulated the devel-
opment of new HRV analyses (Wagner and Persson 1998), 
but has left the clinical utility an open issue. Comparative 
tests among algorithms in retrospective data suggest that the 
time-dependent nonlinear algorithms that treat the problem 
of nonstationary data show the greatest promise for clinical 
HRV analyses (Skinner et al 1998, 2007; Braun et al 1998; 
Marwan et al 2002). Our objective was to evaluate prospec-
tively the ability of one such nonlinear method, the Point Cor-
relation Dimension method (PD2i), to predict documented 
VF and presumed AD (Hinkle and Thaler 1982; Bigger et al 
1999) in high-risk chest-pain patients upon presentation to 
the emergency department (ED).
Methods
Study design
The intended clinical data were from a random sample of 
consecutively enrolled patients at 6 urban teaching hospitals; 
for patient safety in a busy ED, not all subjects could be 
consecutive. Exclusions were patients with atrial ﬁ  brillation 
or pacemakers, as they do not have a normal sinus rhythm. 
Each subject was evaluated in the ED by a validated clinical 
protocol (Lee et al 1991) that incorporates history, clinical 
symptoms, and conventional ECG ﬁ  ndings to determine risk 
for MI. Patients with risk  7% for an AMI were enrolled 
after informed consent was obtained. A digital ECG was 
recorded by a small battery-powered device (Vicor PD2i 
Cardiac Analyzer, digitization 1,000 Hz/channel; band-pass 
0.1–1000 Hz; noise 2 microvolts RMS). Each digital ECG 
(lead V3–V5) contained  1,000 heartbeats (15- to 20-min 
sample). All clinical evaluations were performed by an 
attending emergency physician who was blinded to the digital 
ECG data. Analyses of the high-resolution ECGs were made 
without knowledge of the clinical data.
Patient follow-ups for clinical events were performed at 
3 months and 1 year. Death searches by the Social Security 
Administration (SSA) conﬁ  rmed or complemented some 
in-patient and out-patient clinical data. Subgroups were 
assigned as in-hospital AMI or no AMI (no AMI) and history 
of prior MI (postMI) or no history of MI (no postMI).
The protocol was approved by each local Institutional 
Review Board and conformed to the principles outlined in 
the Declaration of Helsinki. The patient’s identities were 
safeguarded within each hospital’s database and only coded 
identiﬁ  ers were used by the clinical investigators. A Data 
Safety and Monitoring Board of 5 independent ED physicians 
provided additional patient safety.
Clinical outcome measures 
and classiﬁ  cation
Primary clinical outcome measures were: 1) all-cause death, 
2) documented fatal arrhythmias, and 3) presumed arrhyth-
mic deaths, using Hinkle-Thaler criteria (Hinkel and Thaler 
1981) as more recently used by Bigger and associates (Bigger 
et al 1999) to assess mechanism of out-of-hospital deaths. 
A 3-member Events Committee blinded to the digital ECG 
data reviewed each death to ascertain its location, underlying 
cause, probable mechanism, and associated acute cardiac 
symptoms. When modiﬁ  ed Hinkle-Thaler data were incom-
plete, available clinical information was used, including the 
in-hospital documentation of ventricular arrhythmias and 
abnormal ECGs and the occurrence of out-of-hospital death 
without evidence of respiratory obstruction, hemorrhage, 
infection, or stroke. The judged AD designation could be with 
or without documentation of deﬁ  ned arrhythmias (LaRovere 
et al 1998) or AMI (Beaglehole et al 1987).
PD2i analyses (Vicor 2.0)
For the automated PD2i analysis of the RR intervals, using 
Vicor 2.0 software (Vicor Technologies, Inc., 2300 Cor-
porte Blvd, NW, Boca Raton, FL 33432-7345), the common 
rule developed by Swinney and associates (Kostelich and 
Swinney 1989) was used for determining the minimum 
number of data points (N). Files containing too much 
noise for a valid nonlinear test were a priori excluded by 
examination with the %N Test (Skinner et al 1991, 1993, 
1994, 1998, 2000, 2007; Vybiral and Skinner 1993), which 
does not require removal of outliers, and the Randomized-
phase Surrogate Test (Theiler 1988; Theiler et al 1992), 
which does (ie, arrhythmias and artifacts  3 SD were 
replaced by a linear spline). A priori exclusion is required 
for nonlinear algorithms, as they are sensitive to noise and 
it is known that randomized heartbeat intervals, such as 
those in patients with atrial ﬁ  brillation or high arrhythmia 
rates cannot be analyzed. Files passing these quantitative 
exclusionary tests were further examined and required by Therapeutics and Clinical Risk Management 2008:4(4) 691
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a Noise Consideration Algorithm (NCA) to have the back-
ground noise below the ±5 integer noise-tolerance level 
of PD2i. Such tolerated noise in nonstationary data with 
known degrees of freedom does not signiﬁ  cantly alter the 
mean PD2i values (Skinner et al 1994).
The cut-point selected for the PD2i Test (minimum 
PD2i   1.4) was based on our previous retrospective study 
in patients with nonsustained ventricular tachycardia (VT) 
(triplets to less than 30-sec runs of VT) in which the separator 
between the ventricular ﬁ  brillation (VF) and nonVF patients 
was clearly a minimum PD2i score in the 1.21 to 1.40 bin, that 
is, PD2i  1.4 (Skinner et al Vybiral 1993). Receiver-Operator 
Curves (ROC) for the present data were used to determine the 
validity of the minimum PD2i  1.4 cut-point.
Statistical analysis
Because the distribution of the outcomes could not be pre-
sumed to be normal, the nonparametric binomial-probability 
statistic or Fischer Exact Test for contingency tables was 
used to assess the signiﬁ  cance of death-outcome prediction 
by the PD2i of the heartbeats. The sensitivity, speciﬁ  city, 
negative predictive value, and relative-risk statistics assessed 
predictability, using Fisher’s Exact Test to determine the 
signiﬁ  cance of each true-false vs alive-deceased contingency. 
Power was determined using the proportions method of Fleiss 
(Fleiss 1981, power   90%).
Parametric t-tests were used to compare algorithmic 
results from RR data with their surrogates. Each test 
had  1,000 data points and an approximately unit-normal 
distribution (Schreiber and Schmitz 1996). One-tailed 
α-levels were used for the surrogate tests, as the null hypoth-
esis is directional.
The test for homogeneity between 2 enrollment periods 
was performed using the Breslow-Day Test for homogeneity. 
Other tests were used to express statistical signiﬁ  cance of 
PD2i prediction of adjudicated AD: the Cochran-Mantel-
Haenszel statistic (based on table scores) and estimates of 
common Relative Risk (Mantel-Haenszel statistics, and 
Logit, which is an odds ratio). For combining data from the 
two enrollment periods, a ﬁ  xed-effects approach was used 
to sum across the probabilities for calculating contingency 
table statistics, using 3 different scenarios for counting ADs, 
including those ADs with rejected PD2i tests.
Cox proportional hazards models were ﬁ  tted to determine 
what set of risk factors would predict AD. These models 
were ﬁ  tted using a stepwise selection procedure in SAS Proc 
PHREG. All statistics were calculated by a professional 
statistician, using software packages of SAS and Prism.
Results
Clinical characteristics
The study enrolled a total of 918 patients, 335 between 1998 
and 1999 and 583 between 2004 and 2006. Each of the 918 
was an ED patient that had risk for AMI  7% by the Lee 
et al (1991) chest-pain algorithm. There were 56 all-cause 
deaths within 1 year of follow-up, 35 in the 1998–1999 
patients and 21 in the 2004–2006 patients. Of these 56 deaths 
29 (52%) were classiﬁ  ed by the Events Committee as AD 
and 27 as nonAD.
Follow-up was relatively complete in the ﬁ  rst enrollment 
period, as the SSA search of death certiﬁ  cates left only 8 (2.3%) 
lost to follow-up. In the second enrollment period SSA assistance 
was not available and left 34 (5.8%) lost to follow-up. These 
42 patients were eliminated from study, the majority of which 
were PD2i-negative (36 PD2i-neg, 3 PD2i-pos, 3 PD2i-rej). 
Fifty-seven others either had no protocol ECGs recorded or 
withdrew consent, leaving 819 with complete data.
Table 1 shows the clinical characteristics of the com-
bined study cohort and those parceled out because of loss 
of follow-up or no ECG or consent. Each row is either an 
average or percentage for the number in the column category. 
The two groups that could not be studied (columns 3 and 4) 
tended to be the same in their clinical characteristics as the 
population studied, except for a slightly higher percentage of 
males in the lost to follow-up (Chi-square, p   0.01).
Contingency table for primary 
PD2i results
Table 2 shows achievement of high sensitivity, speciﬁ  city, 
negative predictive value, and relative risk statistics for the 
Table 1 Clinical characteristics of study cohort
  Enrolled  Lost to   No ECG
Clinical patients1  follow-up2 or  consent3
characteristic N  = 918  N = 42  N = 57
Average age  63  51  66
Average LVEF  50  52  47
% Male  52*  75*  58
% Diabetic  23  31  25
% Hypertension  57  53  55
% CHF  10  7  11
% Prior MI  25  21  28
% Current AMI  21  14  26
1Caucasian 73%, Afro-American 24%, [Hispanic (all nonAfro) 7%], Asian 3%.
2Lost to follow-up (4.6%); 36 PD2i-Neg; 3 PD2i-Pos, 3 PD2i-Rej.
3No ECG recorded or patient withdrew consent (6.2%).
*Different from enrolled, p   0.001 (Chi-square); all others are nonsigniﬁ  cant.
Abbreviations: AMI, acute MI; CHF, congestive heart failure; MI, myocardial infarction; 
LVEF, left ventricular ejection fraction.Therapeutics and Clinical Risk Management 2008:4(4) 692
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combined enrollment periods. These results are dependent, 
however, upon the considerations of noise in the RR data. The 
89 PD2i-rejected patients, of the 819 patients with complete 
data (10.86%), were rejected by both the Randomized Phase 
Surrogate Test (inverse Fourier with random phases) and the 
%N Test (% accepted PD2i/total PD2i). The %N Test does 
not require the removal of outliers in the RR interval data, 
as does the Surrogate Test. Both tests excluded the same 
subjects. These PD2i-rejected subjects included all cases of 
supraventricular arrhythmia and/or ventricular ectopy, with 
net arrhythmia rates being  10% of beats.
The sensitivity at 30 days was 100%, speciﬁ  city 80%, and 
relative-risk  22.4 (p   0.001, power   90%); these values 
are similar to those at 365 days: sensitivity = 96%, speciﬁ  c-
ity = 85%; relative-risk  24.2 (p   0.001, power   90%). 
Relative-risk is a statistic that considers the true-positive/
false-negative ratio (TP/FN) adjusted for test proportions, 
and it emphasizes the impact of the medically undesirable 
FN type of error. The single FN is a result that also gives 
the negative predictive value such a high percentage (99%). 
The positive predictive value was not signiﬁ  cant, as only 26 
of the 129 PD2i-positive cases died. The 103 false-positives 
(FPs), however, were in hospital and treated (angina, 3; 
unstable angina, 23; coronary artery disease, 38; AMI, 11; 
cardiac heart failure, 22).
PD2i was also found to be a statistically signiﬁ  cant 
predictor of AD in the AMI subgroup (relative-risk = 7.39, 
p   0.001), but not in the postMI subgroup. Beta-blocker 
therapy did not completely prevent AD, but tended to reduced 
its rate: 6 ADs in the 384 patients on beta-blockers; 23 ADs 
in the 435 patients not on beta-blockers.
The Cox proportional hazards model examined risk 
factors. The following variables were considered: age, 
gender, current beta-blocker use, concomitant beta-blocker 
use, diagnosis of AMI, cardiac heart failure, unstable 
angina, angina, or history of coronary artery bypass graph, 
catheterization, coronary artery disease, diabetes mellitus, 
hypertension, previous MI, and the PD2i Test. Two mod-
els were ﬁ  tted to the data using separate approaches, one 
including the enrollment period as a covariate forced into 
the model, and one where enrollment period was consid-
ered as another possible covariate, but not forced into the 
model. The results indicated that enrollment period was 
not predictive of AD; the model where it was included was 
very similar to the one where it was not included. In each 
model there were only 3 variables that were identiﬁ  ed as 
signiﬁ  cant predictors of AD – age, diagnosis of AMI, and 
PD2i Test. In the model with enrollment period included 
as a covariate, the hazard ratio for PD2i Test was 95.6 
(p   0.0001), for age was 1.04 (p   0.01) and for AMI 
was 5.0 (p   0.0001).
Table 3 shows the distribution of the outcomes (columns) 
expressed according to the clinical characteristics (rows) for 
the patients with complete data. There were 89 who had PD2i 
Test rejection due to high arrhythmia rate (11%), and these 
contained 2 with AD. The percentages in column 2 are dis-
tributed for each row in the columns to the right. For example, 
21% of the patient population had documented AMI, and the 
majority (18%) were PD2i-negative and did not manifest 
AD. The 100% of the PD2i tests had 11% rejected, with the 
remainder distributed across the outcome groups.
Test for homogeneity of the two 
enrollment groups
The test for homogeneity is presented for each of three ways 
to consider the impact of the two AD patients with their PD2i 
tests rejected:
1) Standard Analysis (S) uses only data where the PD2i 
device gave a positive or negative reading (ADs with 
rejected PD2i Test are not considered);
2) Conservative Analysis (C) uses the data from the ﬁ  rst 
analysis, but considers the two ADs as PD2i failures;
3) Best Analysis (B) uses the data from the ﬁ  rst analysis, but 
considers the two ADs as PD2i successes.
The third approach would give the highest (best) pos-
sible predictive results for the PD2i device, but it is biased 
toward statistical signiﬁ  cance and included only for com-
parison with the other two. The Breslow-Day Test results 
for the three scenarios are shown in Table 4. There were no 
signiﬁ  cant probabilities to suggest that the two enrollment 
periods are different, therefore the two enrollment groups 
may be combined.
Table 2 Contingency table for primary results
ER study
6 Tertiary-care hospitals
918 Total enrolled, 819 completed study
   AD  no AD
 PD2i  Pos 26  TP 103  FP
 PD2i  Neg 1  FN  595  TN
Sensitivity = 26/(26 + 1) = 96%*
Speciﬁ  city = 595/(595 + 103) = 85%*
Negative predictive value = 595/(595 + 1) = 99%* 
Positive predictive value = 26/(26 + 103) = 20%
Relative risk = 26/1 × (595 + 1)/(26 + 103) = 24.2*
*p   0.01, Fisher’s Exact Test for contingency tables.
Abbreviations: AD, arrhythmic death; TP, true positive; FP, false positive; FN, false 
negative; TN, true negative.Therapeutics and Clinical Risk Management 2008:4(4) 693
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The overall odds ratio is very large and highly signiﬁ  -
cant for each of the three scenarios, suggesting that indeed 
there is a strong relationship between the PD2i positive 
results and mortality and the PD2i negative results and 
patients surviving (Cochran-Mantel-Haenszel: S, 52.8947; 
C, 26.8287; B, 78.9448; p   0.0001). Also the estimates 
of the common relative risk for each scenario are highly 
significant (case control: S, 57.5742; C, 15.0840; B, 
79.6052; p   0.001).
Receiver-operator curve for 
examination of PD2i cut-point
Figure 1 shows the ROC plotted for all data with positive or 
negative PD2i tests. The ROC examines various cut-points 
for the PD2i Test to ﬁ  nd the one that maximizes sensitivity 
and speciﬁ  city. There is a sharp break in the ROC at the 
cut-point, PD2i  1.4. The sensitivity (96%) and speciﬁ  city 
(85%) are maximized at this value, with the area under the 
curve being large (area = 0.9225).
Sample RR intervals and PD2i
Figure 2 shows sample data from two typical ED patients. 
One suffered AD within 24 hours and the other was dis-
charged from the hospital after 24 hours with a diagnosis 
of esophageal reﬂ  ux, so is a normal control (CONTROL). 
Note in the PD2i trace of the AD patient that a relatively 
sustained excursion occurs (underline), that is followed by a 
PD2i increase and then a transient low-dimensional excursion 
(arrow). These two PD2i patterns each indicate PD2i  1.4 
and are typical of what constitutes a positive PD2i test.
All-cause death
Figure 3 shows the accumulative all-cause deaths as a func-
tion of the time of death after the ECG recording. Most ADs 
occurred within 180 days after the recording of the ECG. 
Most of the nonAD deaths (unﬁ  lled squares) occurred in 
elderly subjects (Elderly, mean age 77 years) and after 180 
days. Those nonAD deaths that occurred before 180 days 
had other common mechanisms of death. Eight of the ADs 
at admission were referred to low-level hospitalization 
(Telemetry).
Composite RR interval 
and PD2i results
Figure 4 shows the composite RR data and corresponding 
PD2i values for the ﬁ  rst 18 AD patients that had both the ECG 
and follow-up completed and were not rejected by Surrogate 
or %N Tests (the single False Negative case is omitted, as 
2 of 3 clinical ECGs around the time of the ECG recording 
were normal). These AD patients are compared with 18 AMI 
subjects, associated in both time and ED site with the ﬁ  rst 
18, but none of whom manifested AD within the 1 year of 
follow-up. More than 95% of the accepted PD2is were above 
3.0 for the AMI controls, whereas 95% were below this value 
for the AD patients (Binomial Probability Test, p   0.001; 
sensitivity = 100%; speciﬁ  city = 100%; power   90%).
Discussion
Interpretation of results
The present prospective results conﬁ  rm our earlier studies 
in retrospective data that compared PD2i, Approximate 
Entropy, Detrended Fluctuation Analysis, and other non-
linear HRV algorithms for risk stratiﬁ  cation (Skinner et al 
1993, 1998; Vybiral and Skinner 1993). Similar comparison 
of PD2i with other competing algorithms, including SD of 
Table 3 Clinical characteristics and outcome distributions
   All  PD2i     PD2i 
Clinical   positive    negative
characteristic patients1 Alive2 Died3 Alive4 Died5
% PD2i Test**  100  13  3  73  0.1
Average age*  63  62  72  61  73
Average LVEF  50  52  34  50  None
% Male  52  6  2  44  0
% Diabetic  23  4  1  18  0
% Hypertension  57  9  2  46  0
% CHF  10  3  1  6  0
% Prior MI  25  3  1  21  0
% Current AMI**  21  1  2  18  0.1
1819 with complete data; 11% had PD2i Test rejection (2 ADs).
2103 False positives
326 True positives
4595 True negatives
51 False negative
*p   0.01, **p   0.001 (Cox Proportional Hazards Model)
Abbreviations: AMI, acute MI; CHF, congestive heart failure; MI, myocardial infarc-
tion; LVEF, left ventricular ejection fraction.
Table 4 Test for homogeneity of enrollment groups
Breslow-Day Test for homogeneity of the odds ratios using three 
scenariosa
Chi-square  S 0.9261
  C 2.5088
  B 1.4552
DF  S 1
  C 1
  B 1
Pr   Chi-square  S 0.3359b
  C 0.1132b
  B 0.2277b
aS = Standard; C = Conservative; B = Best.
bnot statistically signiﬁ  cant.Therapeutics and Clinical Risk Management 2008:4(4) 694
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normal beats and power spectral ratios, was made for the ﬁ  rst 
enrollment period subjects and published separately (Skinner 
2007). In both the retrospective and prospective studies, the 
PD2i algorithm had the superior sensitivity and speciﬁ  city 
in all subgroups.
Findings in public data, in which the ECGs were down-
loaded from the internet (PhysioBank; 22 VT/VF patients and 
22 arrhythmia controls), also showed similarly high sensitiv-
ity and speciﬁ  city for the PD2i Test (Skinner et al 2008).
The %N Test was used in all of the previous studies 
to reject data unsuitable for nonlinear analysis because of 
noise content, including the type of noise that results from 
randomized RR intervals. The %N Test in this study rejected 
the same subjects as those rejected by the more complicated 
Surrogate Test. The %N Test does not require removal of 
arrhythmias, artifacts, and other nonstationarities from the 
data. So it would appear to be a sufﬁ  cient test with fewer 
steps in the calculation.
The ROC conﬁ  rms the PD2i  1.4 cut-point used in this 
and all previous studies. The previous retrospective studies 
all predicted VF/VT within 24 hours. The prospective studies, 
including the present one, show that PD2i prediction of AD 
extends outward from days to weeks and months.
Limitations
Nonlinear algorithms require that there be little or no noise 
in the data. Determining the exact methodology for handling 
noise in PD2i analysis of heartbeats remains a challenge. 
Consideration of low-level noise is necessary for achieving 
the high sensitivity and speciﬁ  city of PD2i prediction of AD. 
Even better methods may eventually be found. Patients with 
atrial ﬁ  brillation and arrhythmia rates greater than 10% of 
beats are currently excluded, as they should be, because of 
the randomization that occurs in their heartbeat intervals.
What the PD2i measures
There can be little doubt that cardiac vulnerability to lethal 
arrhythmogenesis is regulated by the brain and autonomic 
nervous system. In animals, blockade of the descending efferent 
pathways at the level of: 1) the frontal cortex (Skinner and Reed 
1981) or amygdala (Carpeggiani et al 1991), 2) the peripheral 
cardiac nerves (Ebert et al 1970), or 3) locations between these 
two sites, in the hypothalamus, mesencephalon, or medulla 
(Skinner and Reed 1981), will each prevent VF after left ante-
rior descending coronary artery occlusion. These same higher 
neural systems also participate in the regulation of heart rate: 
1) the afferent-efferent loops through the medulla underlie the 
baroreﬂ  ex and respiratory sinus arrhythmia; 2) the loops through 
the hypothalamus regulate the affects of blood pH and tempera-
ture; and 3) the loops through the frontal cortex and amygdala 
regulate cerebral defensive reactions (Skinner 1985).
During quiet wakefulness each of these multiple loops 
contributes to the regulation of the RR intervals by its 
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Figure 1 Receiver-operator curve (ROC) for all data with a positive or negative PD2i 
Test. The ROC determines the criterion cut-point for the PD2i Test that maximizes 
the sensitivity and speciﬁ  city. At a cut-point of PD2i   1.4, the maximum sensitivity 
and speciﬁ  city are found with the area under the ROC being high (0.92).
AD
RR
RR
HEARTBEATS
HEARTBEATS
PD2i
PD2i
CONTROL
750
650
500
6
6
0
0
0
0
1000
1000
1000
Figure 2 RR intervals and associated PD2is from two types of patients. Upper panel 
shows RR data and corresponding PD2i results from a patient who experienced 
documented arrhythmic death (AD) within 24 hours; note the two patterns of 
either a sustained low-dimension (line) or the systematic low-dimensional excursion 
(arrow). The lower panel shows data and results from a normal patient discharged 
after diagnosis of gastro-esophageal reﬂ  ux disorder (CONTROL).Therapeutics and Clinical Risk Management 2008:4(4) 695
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interaction on its own time scale. The degrees of freedom 
resulting from the net interactions are approximately 5–6 
in the human (Figure 2, CONTROL). This type of tied-
together regulation results in the erratic RR-interval series 
that is clinically referred to as the “normal sinus rhythm”. 
It is the physiological evolution of abnormal dynamics 
in this tied-together regulation that leads to the type of 
altered HRV that is associated with susceptibility to AD 
in hospitalized patients. This evolved dynamic is associ-
ated with a reduction in the number of degrees of freedom 
(dimensions), as shown in Figures 2–4. The reduction in 
the degrees of freedom in the heartbeats could result from 
greater “cooperation” or phase relationship among the 
independent regulators, each of which accounts for one 
degree of freedom. We do not yet know how this or any 
alternative mechanism may actually produce the changed 
dynamics.
The PD2i algorithm is a new measure of heartbeat 
regulation that, instead of being based on a linear stochastic 
model like the mean, standard deviation, or power spectra, is 
a nonlinear measure of variability not requiring any a priori 
presumptions about an underlying model. The motivation for 
developing the PD2i algorithm was the simple observation 
that the series of heartbeat intervals is not a sequence of 
independent numbers randomly distributed around a mean, 
as is required by any algorithm based on a linear stochastic 
model. An in-depth discussion of these fundamental issues 
(“When the mean is meaningless”) is provided elsewhere 
(Steidl and Meyer 2002, 2003a, b). The poorer perfor-
mance of the linear measures, we believe, results from the 
fundamental misconception that analyzing an inherently 
nonlinear and correlated time series by a linear technique 
is all right. On theoretical grounds this usage commits a 
serious type-II error.
The heart transplant recipient manifests a resting heart-
beat dynamics of PD2i = 1.0, with little beat-to-beat variation, 
although it can slowly change with exercise (Meyer et al 
1996). This denervation result indicates that the nervous 
system produces the higher degrees of freedom found in 
the heartbeat intervals of the intact subject. Besides the 
Figure 3 All-cause death vs time of occurrence after the brief ECG recording. Large squares indicate cardiac arrhythmic death (AD), as adjudicated by the Events Committee. 
All non-AD deaths are indicated by small unﬁ  lled squares, and include deaths due to cancer, sepsis, stroke, etc. AD patients admitted to low-level telemetry observation at 
admission are indicated by dots.
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Figure 4 Composite RR and PD2i results for the ﬁ  rst 18 arrhythmic death (AD) cases with all clinical data and no a priori exclusions for noise contamination. NCA = cases in 
which a single bit (noise-bit) was removed from each data point thus forcing the background noise level below ± 5 integers. In the acute myocardial infarction (AMI) controls 
all PD2i  3.0 are pushed down to the 3.0 line for display.
denervation, the lowering of the heartbeat PD2i to 1.0 can be 
achieved in animals by blockade of the N-methyl-D-aspar-
tate (NMDA) receptors, which are the synaptic mediators in 
virtually all of the higher cognitive and autonomic regulatory 
centers in the brain (Skinner et al 2000).
In summary, the PD2i measures the time-dependent 
degree of interaction or “cooperation” among the compet-
ing neural loops that simultaneously control the dynamics 
of the cardiac rhythm and the vulnerability to lethal 
arrhythmogenesis. Breakdown of the independent cou-
pling among these competing autonomic nervous loops 
(ie, PD2i   1.4) sets the stage for the evolution of lethal 
arrhythmogenesis. The mechanism for the coordination 
of such “cooperation,” although unknown, is certainly 
neural, as there can be little doubt that the coordination is 
organized within the brain and is projected onto the nodal 
and ventricular tissues of the heart through the autonomic 
nervous system.
Conclusions
We conclude that a rapid, accurate, and cost-effective 
assessment of risk of sudden AD can be made by the PD2i 
Test (Vicor 2.0) for patients presenting in the Emergency 
Department with a risk of AMI  7%. The  99% negative 
predictive value for AD indicates that the PD2i Test is able 
to deﬁ  ne a very low risk population.
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